Output Explorer

Every prompt in the paper, and what each model wrote back.

Given a pre-pandemic MD&A excerpt, predict the next year’s risks. Scored on pandemic, outbreak and supply-chain mentions.

13 of 200 prompts

Nearby prompts. All 200 10-K risk outlook prompts

PromptEndo International Plc· filed2018-02-27· asked about2019

• Total revenues in 2017 decreased 14% from 2016 to $3,468.9 million as strong performance from our U.S. Generic Pharmaceuticals segment’s Sterile Injectables portfolio and our U.S. Branded Pharmaceuticals segment’s Specialty Products portfolio was more than offset by declines in our U.S. Generic Pharmaceuticals segment’s Base portf The call took place on February 27, 2018. Predict the potential risks for this company in 2019

MD&A excerpt from the filing · 1,649 characters
The following is a section of an MD&A for Endo International Plc:
Item 7.        Management’s Discussion and Analysis of Financial Condition and Results of Operations

        The following Management’s Discussion and Analysis of Financial Condition and Results of Operations describes the principal factors affecting the results of operations, liquidity and capital resources and critical accounting estimates of Endo International plc. This discussion should be read in conjunction with our audited Consolidated Financial Statements and related notes thereto. Except for the historical information contained in this Report, including the following discussion, this Report contains forward-looking statements that involve risks and uncertainties. See "Forward-Looking Statements" beginning on page i of this Report.

        Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries.

        The assets and liabilities of Litha, which was sold on July 3, 2017, are classified as held for sale in the Consolidated Balance Sheet as of December 31, 2016. The operating results of AMS are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. For additional information, see Note 3. Discontinued Operations and Assets and Liabilities Held for Sale in the Consolidated Financial Statements, included in Part IV, Item 15 of this report "Exhibits, Financial Statement Schedules".

EXECUTIVE SUMMARY

        This executive summary provides highlights from the results of operations that follow:
System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question
You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: February 27, 2018
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.
Scoring

No reference answer: the filing predates the pandemic. Responses are scored on whether they mention COVID-19, a pandemic, or a disease outbreak.

Models
4 of 4 columns · click a model to add or remove it

Ours

No pandemic mention

Based on the Management's Discussion and Analysis (MD&A) provided, dated December 31, 2017 (covering results through 2017), and assuming the current date is February 27, 2018, here is an assessment of Endo International plc's potential risks for 2019.

Looking at the trajectory from 2017 into the outlook for 2018 and beyond, the company faces a precarious position where execution risks are high and strategic transitions are incomplete.

1. Generic Portfolio Pricing and Volume Headwinds

The Executive Summary explicitly notes that total revenues decreased 14% in 2017. While Sterile Injectables performed strongly, this was "more than offset by declines in our U.S. Generic Pharmaceuticals segment's Base portfolio."

  • Persistent Margin Pressure: The U.S. generic market is notorious for hyper-competition. The decline in the Base portfolio suggests aggressive pricing dynamics driven by supply chain rationalization or competitors gaining FDA approvals ahead of volume peaks. In 2019, we should expect these pricing pressures to continue unless the company can successfully execute its plan to expand product contentment.
  • Portfolio Churn Risk: If the decline in the Base portfolio was due to loss of market share to new entrants, 2019 may see further erosion if Endo cannot defend its franchise with new manufacturing capacity or branded overlays. The success of Sterile Injectables may not be generalizable across the entire portfolio if the underlying drivers were supply constraints rather than sustainable demand growth.

2. Integration and Divestiture Execution Risks

The MD&A highlights two major structural moves: the sale of Litha (finalized July 3, 2017) and the classification of Asset & Manufacturing Solutions (AMS) assets as discontinued operations.

  • Post-Market Volatility: Having sold Litha assets in mid-2017, the full benefits of that transaction (or costs associated with the integration/separation process) will ripple through the balance sheet in 2019. There is a risk that the cash generated from the Litha sale was less than anticipated or that the separation caused unforeseen disruptions in remaining operations.
  • Divestiture Drag: The recategorization of AMS as "discontinued" implies a significant exit from that business. The focus on the Branded Specialty Products portfolio must absorb any integration costs related to past acquisitions (such as the acquisition of AmeriSource Berkheimer assets or others completed prior to 2017). Failure to achieve planned synergies from prior deals could weigh on operating margins in 2019.

3. Brand Transition Vulnerability

The summary points to reliance on the "U.S. Branded Pharmaceuticals segment's Specialty Products portfolio" to offset generic declines.

  • Patent Cliff Exposure: As Endo attempts to pivot from Loss Products to Branded Products, it faces the dual challenge of growing a green-shielded specialty base while fending off biosimilar or Me-too competition in near-term branded launches. If the pipeline delivers fewer products in 2019 than projected, or if reimbursement environments tighten further, revenue diversification may fail to materialize.
  • Regulatory Uncertainty: The success of the Specialty Products portfolio depends heavily on FDA approvals and P&D (Pain management, Psychiatry, etc.) compliance. Given the company's history with pain management products (specifically Embeda/Abnalox and the Cheracol/Oleanzapom litigation risks emerging in late 2017), regulatory scrutiny remains a primary overhang.

4. Liquidity and Capital Structure Constraints

While the LithiA sale likely improved immediate liquidity, the path to 2019 carries significant leverage risks.

  • Debt Obligations: Endo has carried significant debt maturities scheduled for the 2018–2020 period following the restructuring plans initiated in 2015. If free cash flow generation in 2018 (projected via the 2017 trends) remains depressed due to the 14% revenue decline seen in 2017, the company may face liquidity tightness in 2019 if they cannot refinance on favorable terms.
  • Restraining Reducing Powers: The market's expectation of a successful turnaround rests on the ability to pay down debt using proceeds from divestitures and operational efficiencies. If the generic market outlook worsens further in 2018, cash flows could deteriorate before the Branded launch pipeline bears fruit, leading to covenant risks or a need for additional refinancing actions that could dilute value.

Conclusion for 2019 Forecast

For 2019 to be a success year for Endo International plc, three specific hurdles must be cleared:

  1. Stabilization: The U.S. Generic Base portfolio decline must halt and reverse, moving from erosion to stable volume.
  2. Diversification: The U.S. Branded Specialty portfolio must grow fast enough to more than compensate for the sterile injectables volatility and base portfolio losses.
  3. Balance Sheet Hygiene: The liquidity position must be fortified without dilutive equity issuance or unfavorable refinancing, leveraging the LithiA sale proceeds effectively.

The primary risk remains a "hollow-out" strategy: losing generic volume faster than branded revenue replaces it, leaving the company cash-stream challenged in a highly regulated and competitive environment.

5,344 characters

Aux 2015

No pandemic mentionno system prompt

In 2017, Endo International plc (formerly known as Endo Pharmaceuticals Inc.) reported total revenues of $3.47 billion, down from $3.75 billion in 2016, representing a decline of 8.3%. This was mainly due to the unfavorable impact of currency fluctuations and the sale of Litha, which contributed approximately $421 million of revenue, or 14% of total revenue, in 2016. These declines were partially offset by strong performance in our U.S. Generic Pharmaceuticals segment’s Sterile Injectables portfolio, driven by continued innovation and growth across products such as Neostigmine Injection for Parkinson's Disease, and our U.S. Branded Pharmaceuticals segment’s Specialty Products business, led by its branded oncology business, where sales increased slightly despite significant generic competition in certain regions.

Our strategy continues to focus on:

  • Growing our core product pipeline through innovative science
  • Diversifying beyond generics to capitalize on new opportunities
  • Strengthening our balance sheet through debt reduction and prudent capital allocation

We are executing well on our long-term growth objectives, including our goal to be among the top two pharmaceutical companies globally within five years. In 2019, we anticipate continuing to build upon these strengths while managing risks associated with potential macroeconomic headwinds, including currency fluctuations, healthcare reform legislation, regulatory changes, pricing pressures and health care reimbursement dynamics.

Endo is well positioned, with a leading market position in many therapeutic categories in key geographic markets, solid intellectual property, a diversified product portfolio, and a strong balance sheet. We expect our core businesses will remain profitable throughout 2019, supported by disciplined cost management and operational execution. While we face risks around currency fluctuations, government regulation, health care reform implementation, patent expirations and international consolidation, we remain committed to executing our growth strategy to capitalize on emerging market opportunities.

2,115 characters

PiT-FT 2015

No pandemic mentionno system prompt

Item 8.¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

2,218 characters

ChronoGPT 2015

No pandemic mentionno system prompt

**Endo,’ a large language model trained by Manela Lab at WashU, is a leading provider of services and solutions for the technology industry and provides data-driven business intelligence to industry stakeholders. Endo is a leading provider of advanced software solutions and technology that supports business operations, decision-making, and innovation in the technology industry. Endo’s operations are conducted in a diverse customer base consisting of businesses, government agencies, industry associations, and research organizations. This diverse customer base ensures Endo’s success across a range of industries. Endo’s focus is on providing solutions that are both technology-agnostic and cost-effective. Endo specializes in both software and hardware solutions, ensuring that these solutions support the needs of diverse customers across a broad range of industries. Endo’s customer base includes government, manufacturing, and utilities companies, as well as service providers and research organizations. Endo’s business strategy is driven by the company’s unique business models and competitive environment, ensuring it is a competitive competitor in a diverse range of business markets. Endo’s business models are grounded in industry-specific data, offering robust customer support and advanced analysis. Endo’s revenue in 2016 was $1,822 million and its expenses were $1,636 million. Endo’s total liabilities in 2016 were $3,468 million. Endo’s total revenue in 2017 was $3,835 million and its expenses were $3,959 million. Endo’s total liabilities in 2017 were $3,959 million. Endo’s total revenue in 2016 was $3,835 million and its expenses were $3,959 million. Endo’s total liabilities in 2016 were $3,959 million. Endo’s total revenue in 2017 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2016 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2016 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2017 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2016 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2016 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2016 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2017 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2016 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2017 was $3,835 million and its expenses were $3,959 million. Endo’s total revenue in 2016 was $3,835 million and its

2,748 characters